Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants

被引：0
|
作者：
Romain Sechaud
Helen Gu
Gholamreza Rahmanzadeh
Amanda Taylor
Ovidiu Chiparus
Gopal Krishna Sharma
Astrid Breitschaft
Hans D. Menssen
机构：
[1] Novartis Pharma AG,
[2] Novartis Pharmaceuticals Corporation,undefined
[3] Novartis Healthcare Pvt. Ltd.,undefined
[4] Parexel International GmbH,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2024年 / 93卷
关键词：
Midostaurin; Drug–drug interaction; Midazolam; Bupropion; Pioglitazone; Oral contraceptive;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：439 / 453
页数：14
相关论文
共 50 条
  • [21] Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
    Wang, Jing
    Zhang, Zhi-Yi
    Lu, Sharon
    Powers, Dan
    Kansra, Vikram
    Wang, Xiaodong
    SUPPORTIVE CARE IN CANCER, 2019, 27 (03) : 819 - 827
  • [22] Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
    Jing Wang
    Zhi-Yi Zhang
    Sharon Lu
    Dan Powers
    Vikram Kansra
    Xiaodong Wang
    Supportive Care in Cancer, 2019, 27 : 819 - 827
  • [23] Kinetic constants and sample-to-sample variation in the rate of metabolism of two or more substrates for human liver microsomal CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP3A4
    Woodworth, Zell
    Dwyer, L. Anne
    Collins, Lisa
    Graves, Terry
    Helmstetter, Stephanie
    Ogilvie, Brian
    Otwell, Clayton
    Pope, Chad
    Ramsey, Tiffin
    Yerino, Phyllis
    Parkinson, Andrew
    DRUG METABOLISM REVIEWS, 2006, 38 : 64 - 64
  • [24] Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
    Yalkinoglu, Oe.
    Heuer, J.
    Becker, A.
    Krebs-Brown, A.
    Strotmann, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Effect of fifteen CYP3A4 in vitro inducers on the induction of CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP3A5 in plated human hepatocytes: a trend analysis
    Zhang, J. George
    Patel, Reena
    Clark, Robert J.
    Ho, Thuy
    Trisdale, Sarah K.
    Stresser, David M.
    DRUG METABOLISM REVIEWS, 2016, 48 : 84 - 84
  • [26] Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims
    Palacharla, Raghava Choudary
    Nirogi, Ramakrishna
    Uthukam, Venkatesham
    Manoharan, Arunkumar
    Ponnamaneni, Ranjith Kumar
    Kalaikadhiban, Ilayaraja
    XENOBIOTICA, 2018, 48 (07) : 663 - 675
  • [27] Impact of the CYP2C8*3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone
    Aquilante, Christina L.
    Kosmiski, Lisa A.
    Bourne, David W. A.
    Bushman, Lane R.
    Daily, Elizabeth B.
    Hammond, Kyle P.
    Hopley, Charles W.
    Kadam, Rajendra S.
    Kanack, Alexander T.
    Kompella, Uday B.
    Le, Merry
    Predhomme, Julie A.
    Rower, Joseph E.
    Sidhom, Maha S.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (01) : 217 - 226
  • [28] REVERSIBLE AND TIME-DEPENDENT INHIBITION (TDI) OF CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 AND CYP3A4 IN HUMAN HEPATOCYTE SUSPENSIONS BY MODEL INHIBITORS
    Zhang, J. George
    Thuy Ho
    Patel, Reena
    Trisdale, Sarah K.
    Creegan, Tim
    Stresser, David M.
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S57 - S58
  • [29] Brivaracetam CYP2C8 interaction study in healthy subjects
    Hulhoven, R.
    Scheen, A.
    Watanabe, S.
    Valgaeren, A.
    Trocnaru, M. M.
    Sargentini-Maier, M. L.
    Stockis, A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1111 - 1111
  • [30] CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
    Metzger, Ingrid F.
    Dave, Nimita
    Kreutz, Yvonne
    Lu, Jessica B. L.
    Galinsky, Raymond E.
    Desta, Zeruesenay
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, : 657 - 666
12345